Humana Inc. (NYSE: HUM) today announced that it has signed a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, the nation's leading provider of

Humana Inc. (NYSE:HUM) today announced that it has signed a definitive agreement with a consortium of investors to divest all or substantially all of its minority interest in Gentiva, the nation's leading provider of end-of-life services, including hospice and palliative care. The agreement values Humana's minority interest stake at approximately $900 million. Other financial terms were not disclosed. Humana intends to utilize proceeds from the sale for general corporate purposes. The transaction is expected to close in the third quarter of 2026, subject to regulatory approvals and other customary closing conditions, and the company does not anticipate a material impact to 2026 earnings from this pending transaction.

Humana's ownership interest in Gentiva resulted from its earlier acquisition of the remaining interest in Kindred at Home (KAH) in 2021. At that time, Humana indicated its intent to ultimately divest non-core KAH businesses, including hospice, palliative, and personal health care services. In 2022, Humana announced an agreement to divest a majority interest in the Hospice and Personal Care divisions of Humana's Kindred at Home subsidiary (KAH Hospice) to private investment firm Clayton, Dubilier & Rice (CD&R). These divisions were then subsequently restructured into a standalone business and rebranded to Gentiva, which is now the nation's largest end-of-life care provider, with thousands of compassionate clinicians and caregivers providing services at more than 430 locations in 35 states.